Craif
Craif Closes Approximately $33M Series D for Urine-Based Cancer Test
Craif announced $33M in Series D financing on August 18, 2026. Craif closed an approximately $33 million Series D, made up of about $30.7 million in equity and about $3.3 million in debt and co-led by Granite-Integral and Tauns Co., Ltd., bringing total capital raised to roughly $88 million.
Round details
The financing includes backing from Granite-Integral, Tauns Co., Ltd., Unreasonable, X&KSK. The company did not publish a valuation with the announcement.
- Round: Series D
- Capital announced: $33M
- Total funding reported: $88M
- Headquarters: Tokyo, Japan
How the company plans to use the capital
Craif said it will use the proceeds to strengthen its U.S. R&D, prepare for a reimbursement-driven launch of its non-invasive cancer test in the United States, and advance its Japanese regulatory filing for a software-based medical device program targeting pancreatic cancer diagnosis.
Why this matters for GTM teams
Craif, a bio-AI company founded in Japan in 2018, opened a bio-AI laboratory in San Diego in April 2026 and says it is preparing a reimbursement-driven U.S. launch of its non-invasive cancer test.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: Craif Series D announcement.
Company Info
Investors (4)
Share
Related Reports
Armadin Raises $255.5M Series B for Autonomous Security
Armadin raised a $255.5 million Series B co-led by Andreessen Horowitz and Accel to scale its agentic security platform and its research, training, and go-to-market efforts.
Homeward Raises $120M Series D for Cash Offer and Bridge Financing
Homeward raised a $120 million Series D led by Saluda Grade, plus $330 million in asset-backed debt, to expand cash offer and bridge financing for real estate agents.
Varda Raises $251M Series D for Space-Based Pharmaceutical Processing
Varda Space Industries raised a $251 million Series D led by Lux Capital and Natural Capital to scale space-based pharmaceutical processing.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free